Search research articles
Contact Us
Filters
Showing results (21-30 of 33) with videos related to
Page
of 4
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)
P Pautier, N Penel, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2015
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer
A Gonçalves, J-Y Pierga, J-M Ferrero, et al.
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 24, 2021
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis
T Gaillard, M Carton, A Mailliez, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2022
Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188]
T Gaillard, M Carton, A Mailliez, et al.
ESMO Open
|
June 19, 2024
Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study
P Barthélémy, L Albigès, B Escudier, et al.
British Journal of Cancer
|
April 3, 2023
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation
J-S Frenel, A Lusque, S Delaloge, et al.
Breast (Edinburgh, Scotland)
|
November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database
P Gougis, M Carton, C Tchokothe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2001
Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer
M Namer, P Soler-Michel, F Turpin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 18, 2017
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases
Y Loriot, L Pagliaro, A Fléchon, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 33) with videos related to
Sort By:
Page
of 4
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)
P Pautier, N Penel, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2015
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer
A Gonçalves, J-Y Pierga, J-M Ferrero, et al.
ESMO Open
|
August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
R de Wit, C Wülfing, D Castellano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 24, 2021
De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis
T Gaillard, M Carton, A Mailliez, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2022
Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188]
T Gaillard, M Carton, A Mailliez, et al.
ESMO Open
|
June 19, 2024
Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study
P Barthélémy, L Albigès, B Escudier, et al.
British Journal of Cancer
|
April 3, 2023
Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation
J-S Frenel, A Lusque, S Delaloge, et al.
Breast (Edinburgh, Scotland)
|
November 2, 2019
CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database
P Gougis, M Carton, C Tchokothe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 30, 2001
Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer
M Namer, P Soler-Michel, F Turpin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 18, 2017
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases
Y Loriot, L Pagliaro, A Fléchon, et al.
Page
of 4